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ABSTRACT   Fabry disease is a rare genetic disease, and surgical reports for the patients 
with Fabry disease are also rarer.
   A 58-year-old man presented with chest pain. At the age of 40, he commenced dialysis due 
to chronic renal failure and at the age of 50, he developed shortness of breath on exertion, and 
echocardiography showed mitral regurgitation and left ventricular hypertrophy. He was then 
diagnosed with Fabry disease due to decreased alpha-galactosidase activity. This diagnosis led 
to enzyme replacement therapy (ERT). The ERT was effective as he had not never experienced 
further exacerbation of congestive heart failure. While the CHF was put under control, his mitral 
stenosis gradually worsened, and the patient began to have more chest pain and became 
hypotensive. He then referred to our section for mitral valve replacement. His mitral annulus 
was severely calcified and we removed mitral annulus calcification (MAC) at minimum so that 
we could stich needles and implanted mechanical valve. Paroxysmal atrial fibrillation and 
bradycardia made his hemodynamics unstable against ERT, which also caused low dialysis 
efficiency. It took longer than usual to wean him off catecholamines. His hemodynamics 
became more stable and dialysis efficiency generally improved, so he moved from ICU to ward 
on postoperative day 11. On day 32, he was transferred back to the referring hospital for his 
rehabilitation.
   We have reported a surgical case of Fabry disease, that are not only rare but have high 
perioperative risk due to Fabry disease’s specific complications.
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〈Case Report〉
by a deficiency of alpha-galactosidase which 
ca ta lyzes  lysosomes .  An accumula t ion  of 
BACKGROUND
   Fabry disease is a rare genetic disease caused 
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globotriaosylceramide due to the lack of alpha-
galactosidase produces various disorders. Most 
cases have peripheral neuropathy beginning in 
early childhood, and proteinuria gradually emerges. 
A decline of renal function, cardiomegaly and 
diastolic dysfunction usually occur in adulthood. 
Finally, most patients have renal failure and/or heart 
failure１）.
   Some valvular diseases associate with Fabry 
disease. Some cases of aortic regurgitation (AR) and 
mitral regurgitation (MR) were reported１，２）. We 
report here on a case of mitral stenosis with Fabry 
disease in which mitral valve replacement was 
performed. We believe a first case with this special 
condition.
CASE REPORT
   A 58-year-old man presented with chest pain. He 
had a long history of medical problems leading up 
to his complaint. He did not know obvious family 
history. When he was 4 years old, he underwent 
a left nephrectomy. Then at the age of 40, he 
commenced dialysis due to progression of renal 
failure. At the age of 50, he developed shortness of 
breath on exertion, and echocardiography showed 
mitral regurgitation and left ventricular hypertrophy. 
He was then diagnosed with Fabry disease due to 
decreasing of alpha-galactosidase activity. This 
diagnosis led to enzyme replacement therapy (ERT). 
He had been infused agalsidase alfa 3.5mg once 
two weeks since his diagnosis was made. The ERT 
was effective as he had not experienced further 
exacerbation of congestive heart failure (CHF). 
While the CHF was put under control, his mitral 
stenosis gradually worsened, and the patient began 
to have more chest pain and became hypotensive. 
He was taking pain-relieving drugs and even 
narcotic analgesics such as carbamazepine and 
renorphine due to severe pain in his extremities 
since childhood. He had a diastolic heart murmur 
at the apex. There was a internal shunt in his left 
forearm.
   Blood tests showed his hemoglobin was 10.1 g/
dL, creatinine was 11.57 mg/dL, urea nitrogen was 
79 mg/dL, brain natriuretic peptide was 342.8 pg/
ml, and his galactosidase activity was 0.064 nmole/
ml (low activity). The other blood test results are 
shown in Table 1. 
   An electrocardiogram showed a sinus rhythm of 
78 beats per minute and nothing else of significance. 
Posteroanterior radiograms of the chest showed that 
the cardiac silhouette was not enlarged and there 
were no findings to suggest pulmonary edema or 
pleural effusion. There was massive MAC. 
   Transesophageal echocardiography showed severe 
mitral stenosis with a mitral valve area of 0.8 cm2, 
and massive MAC. Other data from the transthoracic 
echocardiography (Fig. 1) showed a left ventricular 
diameter (LVD) of 40 mm (diastolic) and 27 mm 
(systolic), Interventricular septum (IVS) of 12 mm, 
Table 1. Blood test results of this patient on admission
WBC 5.51 103/μL TP 5.1 g/dL CK 41 U/L
RBC 3.26 106/μL Alb 3.3 g/dL Na 140 mmol/L
Hb 10.1 g/dL T-Bil 0.4 mg/dL K 4.4 mmol/L
HCT 29.5 % ALP 341 U/L Cl 106 mmol/L
PLT 34.2 103/μL γGTP 56 U/L P 6.4 mg/dL
PT-sec 12.0 sec LD 144 U/L Ca 7.6 mg/dL
APTT 29.8 sec ChE 360 U/L Mg 1.9 mg/dL
Fib 294 mg/dL ALT 13 U/L
AT-III 77.5 % AST 15 U/L HbA1c 5.3 %
Cre 11.57 mg/dL BNP 342.8 pg/ml
CRP 0.24 mg/dL BUN 79 mg/dL
UA 8.2 mg/dL
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posterior wall (PW) of 13 mm, a left ventricular 
ejection fraction (LVEF) of 65%, an E/A ratio of 
0.5, an e/e’ ratio of 28.7, a deceleration time of 979 
ms and a Tricuspid regurgitation pressure gradient 
(TRPG) of 30mmHg. Coronary angiography showed 
no significant stenosis. His right coronary artery 
was originated from left Valsalva sinus. Computed 
tomography showed MAC at almost entire circle 
(Fig.2).
   Magnetic resonance imaging of brain showed 
some previous lacunar infarctions. We did not take 
MRI image of the heart.
   A cardiopulmonary bypass (CPB) via a median 
sternotomy was established under blood supply 
to the ascending aorta and bicaval drainage. A left 
ventricular venting tube was placed in the right 
superior pulmonary vein. The ascending aorta 
was clamped and antegrade cardioplegia was 
administered. Then the left atrium was opened at 
the interatrial groove. MAC at anterior leaflet was 
mild, and so we could resect anterior leaflet entirely. 
MAC at posterior leaflet was marked, then we 
removed its MAC with a cavitron ultrasonic surgical 





Fig. 1. transthoracic echocardiography
A: parasternal long axis view
B: parasternal long axis view with Doppler
LVH, mitral valve caicification, diastolic mitral jet
Fig. 2. computed tomography shows severe mitral annulus calcification without pulmonary 
edema or pleural effusion 
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leaflet was so minimum that the needles could stitch 
through the annulus. Then a mechanical valve (25 
mm St. Jude mechanical prosthesis) was implanted 
in an intra-annular position. The CPB was easily 
weaned off, and transesophageal echocardiography 
showed none of perivalvular leakage. Microscopic 
examination showed that the excised leaflet was 
composed of hyaline, myxomatous changes and 
massive calcification (Fig.4).
   The patient was extubated on postoperative day 
(POD) 1, and continuous hemodiafiltration was 
commenced on POD 2. Paroxysmal atrial fibrillation 
and bradycardia made his hemodynamics unstable 
against ERT, which also caused low dialysis 
Figure3
Fig. 3. Mitral valve operative view
Removing mitral annulus calcification
Fig. 4.
A: mitral valve anterior cusp myxomatous changes and calcification
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efficiency. It took longer than usual to wean him off 
catecholamines. His hemodynamics became more 
stable and dialysis efficiency generally improved. 
So he moved from ICU to ward on POD 11. On 
POD 32, he was transferred back to the referring 
hospital for his rehabilitation.
   Postoperative transthoracic echocardiography 
showed normal function of mechanical valve leaflets 
without paravalvular leakage. His parameters were a 
LVD of 38mm (diastolic) and 24 mm (systolic), IVS 
of 12 mm, PW of 13 mm, a LVEF of 67%, an E/A 
ratio of 4.4, an e/e’ ratio of 41.6 and a deceleration 
time of 155 ms and a TRPG of 27 mmHg.
DISCUSSION
   Fabry disease is an X-linked genetic disorder. An 
accumulation of ceramide trihexoside (CD77) in the 
skin, peripheral nerves, the heart, blood vessels, the 
kidneys and the brain due to the absence of alpha-
galactosidase causes diverse symptoms１）. Clinical 
diagnosis for Fabry disease is difficult due to its 
rarity. Most patients have had peripheral neuropathy 
and dyshidrosis since childhood. After reaching 
adulthood, renal dysfunction, cardiac dysfunction 
and valvular diseases progress. Some patients get 
finally end-stage renal failure, systolic and diastolic 
cardiac dysfunction with/without heart failure１）. 
In this case, the patient had peripheral neuropathy, 
gradually progressing renal dysfunction, left 
ventricular hypertrophy and valvular disease. His 
symptoms fit the criteria for a classic case of Fabry 
disease.
   Enzyme replacement therapy (ERT) can improve 
the prognosis of Fabry disease, especially when 
applied before the beginning of renal or heart 
failure. Beck et al.３） reported that agalsidase alfa 
slowed the progression of renal dysfunction and 
cardiomyopathy, and also slowed the development 
of complications and death. Kampmann et al. 
reported４） on 10  years effects of ERT, and 
concluded that ERT improved the New York Heart 
Association (NYHA) Classification for heart failure 
for most patients with Fabry disease. In this case, 
his NYHA Classification clearly improved after 
beginning ERT.
   Some patients with Fabry disease have valvular 
diseases, mostly aortic regurgitation and/or mitral 
regurgitation, with rare cases of aortic stenosis. 
Weidemann et al.２） reported on cases of valvular 
disease associated with Fabry disease. Of 111 
patients with Fabry disease, 59 patients had mitral 
regurgitation (57 mild, 2 moderate), while 18 had 
aortic regurgitation (17 mild, 1 moderate). There 
were also 2 cases of aortic stenosis but no cases 
of mitral stenosis. There are no previous report 
of mitral stenosis with a patient of Fabry disease 
and also no previous surgical case reports of such 
a condition. Our case had mild MR and mild AR, 
which did not progress after the introduction of 
ERT. However, the mitral stenosis became severe. 
We believe the progression of mitral stenosis from 
atherosclerotic calcification was due to a long 
history of hemodialysis on the mitral valve along 
with myxomatous changes associated with Fabry 
disease which caused mitral regurgitation (Fig. 4). 
   There are some reports on surgical interventions 
for Fabry disease complications including mitral 
valve repair, aortic valve replacement, coronary 
artery bypass grafting and heart transplantation５－８）. 
There are no previous reports about surgical 
intervention for mitral stenosis of a patient with 
Fabry disease. Some reports showed valvular 
myxomatous degradation similar to our case５，６）. 
   Patients with Fabry disease may have atrial, 
ventricular or bradycardiac arrhythmias９）. Our 
case had a history of exacerbation of congestive 
heart failure triggered by atrial fibrillation and he 
was performed a catheter ablation at the referring 
hospital. Even so, it took a long time to stabilize 
his postoperative hemodynamic status due to 
paroxysmal atrial fibrillation and bradycardia.
   Though we could not take myocardial biopsy, it 
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was reported that there is marked vacuolation within 
the cytoplasm of cardiomyocytes, and electron 
microscopy demonstrates dense lamellar deposits 
of globotriaosylceramide within lysosomes. And it 
also reported interstitial fibrosis was evident with 
a subepicardial or mid-wall pattern of fibrosis, 
it became more extensive in the posterolateral 
basal portion of the left ventricle, but myocardial 
scarring is not commonly associated with aneurysm 
formation10）.
   Left ventricular hypertrophy, together with 
diastolic and systolic dysfunction, make the 
postoperative management difficult. Toda et 
al.11） reported that diastolic dysfunction is one 
specific cause of cardiomyocyte injury. Merello 
et al.12） reported that in patients who received a 
coronary artery bypass grafting (CABG), diastolic 
dysfunction with an E/A ratio > 1.5 and an early 
filling deceleration time < 150 ms actually have 
a higher risk of morbidity and mortality than the 
risk shown by both the Euroscore and Parsonnet 
score risk models. Severe diastolic dysfunction is 
a predictive factor of adverse postoperative events. 
The Euroscore and Parsonnet score risk models may 
not accurately reflect some important risk factors.
   In this case, a preoperative echocardiography 
showed an E/A ratio of 0.5, an e/e’ ratio of 28.7, 
however a postoperative echocardiography showed 
an E/A ratio of 4.4, an e/e’ ratio of 41.6. The 
preoperative result did not directly mean as diastolic 
dysfunction due to mitral stenosis. The postoperative 
echocardiography meant that he had grade I diastolic 
dysfunction as defined by the American Society 
of Echocardiography and European Association 
of Cardiovascular Imaging guidelines13）. Even 
though his preoperative Euroscore was only 3.83, 
postoperative hemodynamic instability which 
needed catecholamines longer and refractory 
arrhythmias revealed that he actually had a higher 
risk than initially indicated.
   It might seem that the postoperative course of this 
case was similar to the patients with severe MAC 
and chronic atrial fibrillation without Fabry disease. 
We think it was because ERT stabilized heart 
failure of this patient. There is a great difference in 
surgical risks between the patients with preoperative 
heart failure and the patients without it. So, the 
perioperative approaches have a great difference 
between them. ERT could possibly lower the 
surgical risk if the surgical case was with Fabry 
disease. 
   There were 0.9- 4.0% of patients who were 
diagnosed as Fabry disease from the patients 
who were clinically diagnosed as hypertrophic 
cardiomyopathy or left ventricular hypertrophy14，15）. 
We might meet patients with Fabry disease actually 
more than we have known. And the emerge of ERT 
have those patients live longer and could cause 
valvular stenosis as had happened to this case. 
There may be more patients of mitral stenosis with 
hemodialysis who actually has Fabry disease.
CONCLUSIONS
   We exper ienced a  rare  surgical  case  of 
mitral stenosis for a patient with Fabry disease 
complicated with hemodialysis. The risk of surgery 
is suspected to be higher than the established risk 
model calculations due to the characteristics of 
cardiomyopathy and arrhythmia. It should be sure 
that the patients with Fabry disease has commenced 
on ERT before the surgery to stabilize their heart 
failure and to lower the surgical risks.
ABBREVIATIONS
   AR: Aortic regurgitation, MR: mitral regurgitation, 
ERT: enzyme replacement therapy, CHF: congestive 
heart failure, LVD: left ventricular diameter, 
IVS: Interventricular septum, PW: posterior wall, 
LVEF: left ventricular ejection fraction, TRPG: 
Tricuspid regurgitation pressure gradient, CPB: 
cardiopulmonary bypass, POD: postoperative day, 
NYHA: New York Heart Associations, CABG: 
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coronary artery bypass grafting.
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